Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
Rani Therapeutics Holdings, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/11/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/11/2023 8-K Quarterly results
Docs: "Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update - Expansion of partnership with Celltrion for development of RT-105 to complement existing partnership for RT-111 - Appointment of Kate McKinley as Chief Business Officer - Presentation of three abstracts on RT-102 and RT-112 at the Endocrine Society Annual Conference and selection as winner of Presidential Poster Competition in its category for exceptional scientific work on RT-102 - Presentation of late-breaking abstract on oral delivery of GLP-1 agonist at American Diabetes Association’s Scientific Sessions - Plan to initiate Phase 2 study for RT-102 and Phase 1study for RT-111 in 2H of 2023 SAN JOSE, Calif., August 11, 2023"
08/08/2023 4 McKinley Kate (CHIEF BUSINESS OFFICER) has filed a Form 4 on Rani Therapeutics Holdings, Inc.
Txns: Granted 250,000 options to buy @ $4.13, valued at $1M
08/08/2023 3 McKinley Kate (CHIEF BUSINESS OFFICER) has filed a Form 3 on Rani Therapeutics Holdings, Inc.
05/30/2023 4 IMRAN MIR A (Director) has filed a Form 4 on Rani Therapeutics Holdings, Inc.
Txns: Granted 101,276 options to buy @ $4.11, valued at $416.2k
05/30/2023 4 Nanavaty Maulik (Director) has filed a Form 4 on Rani Therapeutics Holdings, Inc.
Txns: Granted 101,276 options to buy @ $4.11, valued at $416.2k
05/30/2023 4 Rometty Lisa Ann (Director) has filed a Form 4 on Rani Therapeutics Holdings, Inc.
Txns: Granted 101,276 options to buy @ $4.11, valued at $416.2k
05/30/2023 4 DEBUONO LAUREEN (Director) has filed a Form 4 on Rani Therapeutics Holdings, Inc.
Txns: Granted 101,276 options to buy @ $4.11, valued at $416.2k
05/30/2023 4 BUTEL JEAN LUC (Director) has filed a Form 4 on Rani Therapeutics Holdings, Inc.
Txns: Granted 101,276 options to buy @ $4.11, valued at $416.2k
05/30/2023 4 Ausiello Dennis A (Director) has filed a Form 4 on Rani Therapeutics Holdings, Inc.
Txns: Granted 101,276 options to buy @ $4.11, valued at $416.2k
05/30/2023 4 Farquharson Andrew (Director) has filed a Form 4 on Rani Therapeutics Holdings, Inc.
Txns: Granted 101,276 options to buy @ $4.11, valued at $416.2k
05/10/2023 4 South Cone Investments Limited Partnership (10% Owner) has filed a Form 4 on Rani Therapeutics Holdings, Inc.
Txns: Bought 4,420 shares @ $4.4645, valued at $19.7k
05/10/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/10/2023 8-K Quarterly results
Docs: "Rani Therapeutics Reports First Quarter 2023 Financial Results; Provides Corporate Update - Announced partnership with Celltrion on development of RT-111, a RaniPill GO capsule containing a biosimilar for the monoclonal antibody ustekinumab - - Received preliminary feedback from FDA on RT-102 development plans; 505 pathway for RT-102 could be suitable - - Initiation of Phase 2 clinical trial for RT-102 for the treatment of osteoporosis expected in 2H of 2023 - SAN JOSE, Calif., May 10, 2023"
05/05/2023 4 South Cone Investments Limited Partnership (10% Owner) has filed a Form 4 on Rani Therapeutics Holdings, Inc.
Txns: Bought 2,040 shares @ $4.8118, valued at $9.8k
05/02/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/26/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/24/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/20/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/18/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/14/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/06/2023 4 South Cone Investments Limited Partnership (10% Owner) has filed a Form 4 on Rani Therapeutics Holdings, Inc.
Txns: Bought 4,416 shares @ $5.4906, valued at $24.2k
Bought 7,280 shares @ $5.487, valued at $39.9k
04/05/2023 8-K Other Events  Interactive Data
04/05/2023 4 South Cone Investments Limited Partnership (10% Owner) has filed a Form 4 on Rani Therapeutics Holdings, Inc.
Txns: Bought 3,587 shares @ $5.2268, valued at $18.7k
04/03/2023 4 South Cone Investments Limited Partnership (10% Owner) has filed a Form 4 on Rani Therapeutics Holdings, Inc.
Txns: Bought 12,230 shares @ $4.7901, valued at $58.6k
Bought 751 shares @ $5.0476, valued at $3.8k
03/29/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/29/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/29/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/29/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/24/2023 4 Sanford Svai S (CFO) has filed a Form 4 on Rani Therapeutics Holdings, Inc.
Txns: Paid exercise price by delivering 3,355 shares @ $5.95, valued at $20k
03/24/2023 4 Imran Talat (CEO) has filed a Form 4 on Rani Therapeutics Holdings, Inc.
Txns: Paid exercise price by delivering 7,988 shares @ $5.95, valued at $47.5k
03/24/2023 4 Groen Eric (General Counsel) has filed a Form 4 on Rani Therapeutics Holdings, Inc.
Txns: Paid exercise price by delivering 2,498 shares @ $5.95, valued at $14.9k
03/24/2023 4 Hashim Mir (Chief Scientific Officer) has filed a Form 4 on Rani Therapeutics Holdings, Inc.
Txns: Paid exercise price by delivering 4,201 shares @ $5.95, valued at $25k
03/22/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy